Imvexxy – Another Estradiol Vaginal Insert for Dyspareunia

Abstract

The FDA has approved an estradiol softgel vaginal insert (Imvexxy -TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is the second estradiol vaginal insert to be approved in the US; Vagifem, an intravaginal tablet formulation, was the first. 1 Vagifem and Imvexxy are both available in inserts containing 10 μg of estradiol; Imvexxy is also available in a 4-μg strength.